Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03412812 · ClinicalTrials.gov registry record · NA
A Dose Escalation Trial of Five Fraction Stereotactic Radiation Therapy for Brain Metastases
A NA study, sponsored by University of Alabama at Birmingham.
- Completed
- Registry status
- NA
- Development phase
- 13
- Enrollment target
NCT03412812 is a NA study that has completed, run by University of Alabama at Birmingham. The registered enrollment target is 13 participants.
The verdict
NCT03412812, a NA study, has completed, sponsored by University of Alabama at Birmingham.
- COMPLETED
- Registry status
- NA
- Development phase
- 13 participants
- Enrollment target
Study Summary
This study looks at dose escalation for five fraction stereotactic radiotherapy for patients diagnosed with brain metastases with tumors 2.1-4.0 cm in diameter or 4.1-6.0 cm in diameter.
Interventions
- RADIATION 6 Gy
- RADIATION 7 Gy
- RADIATION 8 Gy
- RADIATION 9 Gy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2018-07-30 |
| Est. Completion | 2025-10-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03412812
The ClinicalTrials.gov registry entry for NCT03412812 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Alabama at Birmingham, which has 1,160 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which 6 Gy is the first listed.
NCT03412812 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03412812 about?
NCT03412812 is a clinical study titled "A Dose Escalation Trial of Five Fraction Stereotactic Radiation Therapy for Brain Metastases". This study looks at dose escalation for five fraction stereotactic radiotherapy for patients diagnosed with brain metastases with tumors 2.1-4.0 cm in diameter or 4.1-6.0 cm in diameter.
What is the current status of trial NCT03412812?
This trial is currently completed. It is a NA study. The enrollment target is 13 participants. The study started on 2018-07-30. Estimated completion is 2025-10-01.
What interventions are being tested in trial NCT03412812?
The interventions under investigation include: 6 Gy (RADIATION), 7 Gy (RADIATION), 8 Gy (RADIATION), 9 Gy (RADIATION).
Who is sponsoring clinical trial NCT03412812?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.